Baseline Liver Metabolic Health in Newly Diagnosed People Living with HIV Compared with HIV-Negative Controls: Cross-Sectional Findings from the Prospective MASHIV-TR Cohort
Authors:
- Çiğdem MermutluoğluÇMÇiğdem Mermutluoğlu
- Yeşim TaşovaYTYeşim Taşova
- Ayşe Özlem MeteAMAyşe Özlem Mete
- İlkay KaraoğlanİKİlkay Karaoğlan
- Hüsnü PullukçuHPHüsnü Pullukçu
- Meliha Çağla SönmezerMSMeliha Çağla Sönmezer
- Dilara İnanDIDilara İnan
- Funda ŞimşekFŞFunda Şimşek
- Sıla AkhanSASıla Akhan
- Tuba Damar ÇakırcaTÇTuba Damar Çakırca
- Nursel Çalık BaşaranNBNursel Çalık Başaran
- Aslıhan CandevirACAslıhan Candevir
Open Access
- 28 September 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8672
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important comorbidity in people living with HIV (PLWH), yet most data derive from individuals receiving antiretroviral therapy (ART). In the baseline cross-sectional analysis of the prospective multicentre MASHIV-TR cohort (nine centres, Türkiye), we compared 250 newly diagnosed, ART-naïve PLWH and 161 HIV-negative controls. Hepatic steatosis and liver stiffness were assessed by vibration-controlled transient elastography; MASLD was defined as hepatic steatosis, indicated by CAP ≥ 248 dB/m together with at least one cardiometabolic risk factor. MASLD prevalence was similar in the two groups (25.2% vs. 30.4%; p = 0.245), and HIV status was not independently associated with MASLD. Triglyceride level was independently associated with CAP in PLWH (+10.69 dB/m per 50 mg/dL) and in controls (+9.26 dB/m), whereas CD4 and CD8 counts, the CD4/CD8 ratio and HIV-RNA were not associated with the liver outcomes. Before ART, hepatic steatosis tracked metabolic rather than HIV-specific markers.Keywords
Funding Information
- İlko İlaç Sanayi ve Ticaret A.Ş. (430011792)
This publication has 49 references indexed in Scilit:
- Metabolic Dysfunction–Associated Steatotic Liver Disease Is Associated With Impaired Health-Related Quality of Life in People With HIVGastro Hep Advances, 2026
- Lipid Profile Differences in HIV‐Infected Populations With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Systematic Review and Meta‐AnalysisChronic Diseases and Translational Medicine, 2025
- Metabolic Complications Associated with Use of Integrase Strand Transfer Inhibitors (InSTI) for the Treatment of HIV-1 Infection: Focus on Weight Changes, Lipids, Glucose and Bone MetabolismCurrent HIV/AIDS Reports, 2024
- Prevalence of metabolic dysfunction-associated steatotic liver disease and steatohepatitis in Türkiye: A forensic autopsy studyHeliyon, 2024
- Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2023
- Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective StudyClinical Gastroenterology and Hepatology, 2022
- Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIVHepatology Communications, 2022
- MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practiceJournal of Hepatology, 2016
- Diagnosis of Fibrosis and Cirrhosis Using Liver Stiffness Measurement in Nonalcoholic Fatty Liver DiseaseHepatology, 2010
- Insulin Resistance: A Metabolic Pathway to Chronic Liver Disease *Hepatology, 2005